Buntanetap

Summary

Buntanetap (CHEMBL4297417) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including parkinson disease and alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 7
• Chemistry: 337.4 Da · C20H23N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297417
Name	Buntanetap
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11249342
Molecular formula	C20H23N3O2
Molecular weight	337.4
InChIKey	PBHFNBQPZCRWQP-AZUAARDMSA-N

SMILES: C[C@]12CCN([C@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C

IUPAC name: [(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate

Also known as: ANVS-401, ANVS401, Buntanetap, Phenserine, (+)-, Posiphen, R-phenserine, BUNTANETAP, PHENSERINE

Parent form; salt/anhydrous children: CHEMBL5095412

Patent coverage: 37 distinct patent families (93 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 89 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Parkinson disease	3	MONDO:0005180	MONDO:0005180
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
neurodegenerative disease	1	MONDO:0005559	EFO:0005772

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	2
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06709014	PHASE3	ACTIVE_NOT_RECRUITING	A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT07284784	PHASE2/PHASE3	RECRUITING	A Study of Buntanetap in Participants With PD
NCT05357989	PHASE3	COMPLETED	A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
NCT05686044	PHASE2/PHASE3	COMPLETED	A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
NCT02925650	PHASE1/PHASE2	COMPLETED	Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer’s Disease
NCT04524351	PHASE1/PHASE2	COMPLETED	Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer’s and Parkinson’s Patients
NCT06774261	PHASE1	COMPLETED	Phenserine on the Alzheimer’s Treatment Horizon, Study 1

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).